Dimensional Fund Advisors LP Has $1.95 Million Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX)

Dimensional Fund Advisors LP grew its stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 14.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 462,950 shares of the company’s stock after purchasing an additional 58,854 shares during the quarter. Dimensional Fund Advisors LP owned about 0.72% of MeiraGTx worth $1,949,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of MeiraGTx by 3.7% during the 1st quarter. Vanguard Group Inc. now owns 323,891 shares of the company’s stock worth $1,966,000 after purchasing an additional 11,470 shares during the last quarter. Privium Fund Management B.V. increased its position in shares of MeiraGTx by 70.0% during the 2nd quarter. Privium Fund Management B.V. now owns 203,960 shares of the company’s stock worth $804,000 after purchasing an additional 83,975 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of MeiraGTx by 1.9% during the 1st quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock worth $959,000 after purchasing an additional 2,994 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of MeiraGTx during the 1st quarter worth approximately $706,000. Finally, Rhumbline Advisers increased its position in shares of MeiraGTx by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock worth $223,000 after purchasing an additional 5,178 shares during the last quarter. Institutional investors and hedge funds own 67.48% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Royal Bank of Canada reduced their target price on MeiraGTx from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and set a $36.00 target price on shares of MeiraGTx in a research note on Wednesday, July 31st.

Insider Activity at MeiraGTx

In other news, Director Perceptive Advisors Llc purchased 1,250,000 shares of MeiraGTx stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $5,000,000.00. Following the purchase, the director now directly owns 12,531,103 shares of the company’s stock, valued at $50,124,412. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.40% of the stock is currently owned by corporate insiders.

MeiraGTx Stock Performance

Shares of NASDAQ MGTX opened at $4.25 on Friday. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 1.04. MeiraGTx Holdings plc has a 12 month low of $3.49 and a 12 month high of $7.60. The stock has a 50 day moving average of $4.16 and a 200-day moving average of $4.68. The company has a market capitalization of $275.83 million, a P/E ratio of -3.04 and a beta of 1.29.

MeiraGTx (NASDAQ:MGTX) last issued its earnings results on Monday, August 12th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.45). The business had revenue of $0.28 million for the quarter, compared to the consensus estimate of $16.38 million. MeiraGTx had a negative return on equity of 152.82% and a negative net margin of 1,146.81%. As a group, equities research analysts predict that MeiraGTx Holdings plc will post -1.37 EPS for the current year.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.